Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The relationship between disease activity and fibrinolytic activity was investigated in 40 patients with rheumatoid arthritis (RA). There was no difference in global fibrinolytic activity between RA and controls, 220 (200-330) and 280 (167-346) min respectively although inhibition of plasminogen activator activity (PAI) was lower in RA 8.2 (5.1-9.7) vs 9.9 (8.0-15.7) IU/ml than controls, p=0.01. There were no significant differences between RA and controls in tPA:Ag 4.8ng/ml (3.1-7.8) vs 7.1(5.2-9.3) or PAI-1:Ag 8.Ong-ml (4.8-10.8) vs 9.1 (3.6-22.3). 9 patients with severe RA received prednisolone 40 mg daily for 7 days. This improved disease activity clinically and was associated with a fall in fibrinogen from 4.4. g/l (3.4-5.2) to 2.32 (2.31-2.63), p<0.0005 and plasminogen from 117.6% (107-121) to 101.5 (88.7-110.4), p<0.005. In addition PAI-1:Ag increased from 5.4ng/ml (2.77-10.38) to 11.0 (4.45-16.65), p<0.005 and PAI from 8.51U/ml (6.49-8.99) to 10.1 (8.5-16.5), p<0.005. In this study PAI was lower in patients with RA. Prednisolone improved disease activity, reduced Fibrinogen and plasminogen and increased PAI and PAI-1:Ag. © 1993.

Original publication




Journal article


Fibrinolysis and Proteolysis

Publication Date





97 - 102